**ARTICLE INFORMATION**

<table>
<thead>
<tr>
<th><strong>Article Type</strong></th>
<th>Research article</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Article Title</strong></td>
<td>Blending three probiotics alleviates loperamide-induced constipation in SD-rats</td>
</tr>
<tr>
<td><strong>Running Title (within 10 words)</strong></td>
<td>Effect of BIOVITA 3 administration on constipation improvement</td>
</tr>
<tr>
<td><strong>Author</strong></td>
<td>Ye-Ji Jang1, Jin Seok Moon1, Ji Eun Kim1, Dayoung Kim1, Han Sol Choi1 and Ikhoon Oh1*</td>
</tr>
<tr>
<td><strong>Affiliation</strong></td>
<td>1 Research Laboratories at ILDONG Pharmaceutical Co. Ltd., Hwaseong-si, 18449, Republic of Korea</td>
</tr>
<tr>
<td><strong>Special remarks</strong> – if authors have additional information to inform the editorial office</td>
<td>-</td>
</tr>
</tbody>
</table>
| **ORCID (All authors must have ORCID) https://orcid.org** | Ye-Ji Jang (https://orcid.org/0009-0004-2510-0697)  
Jin Seok Moon (https://orcid.org/0000-0003-0375-7175)  
Ji Eun Kim (https://orcid.org/0009-0006-6425-8977)  
Dayoung Kim (https://orcid.org/0000-0002-8705-5412)  
Han Sol Choi (https://orcid.org/0000-0002-2991-9091)  
Ikhoon Oh (https://orcid.org/0009-0007-3112-8727) |
| **Conflicts of interest** | All authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. |
| **Acknowledgements** | We would deeply be thankful to Ildong Bioscience Co., LTD for providing the BIOVITA 3 and its three strains used as experimental materials for this study. |
| **Author contributions** (This field may be published.) | Conceptualization: Oh I  
Data curation: Jang YJ  
Formal analysis: Moon JS, Kim D  
Methodology: Kim JE  
Validation: Choi HS  
Investigation: Kim JE  
Writing - original draft: Jang YJ  
Writing - review & editing: All authors |
| **Ethics approval** (IRB/IACUC) (This field may be published.) | This animal study was conducted with the approval of the Experimental Animal Ethics Committee at Dt&CRO (Yongin, Republic of Korea) (approval number: DTE220027). |

**CORRESPONDING AUTHOR CONTACT INFORMATION**

| First name, middle initial, last name | Ikhoon Oh |
| Email address – this is where your proofs will be sent | oih52@ildong.com |
| Secondary Email address | Cucumber0608@naver.com |
| Postal address | 18449 |
| Cell phone number | +82-10-3397-8681 |
| Office phone number | N/A |
| Fax number | N/A |
Abstract

BIOVITA 3 bacterial species (BIOVITA 3), a probiotic blend powder containing *Clostridium butyricum* IDCC 1301, *Weizmannia coagulans* IDCC 1201, and *Bacillus subtilis* IDCC 1101, has been used as a food ingredient for gut health. However, its efficacy in improving constipation has not been reported. Therefore, we aimed to investigate the functional effects of oral administration of BIOVITA 3 as well as its component strains alone (at $1.0 \times 10^9$ CFU/day) in Sprague-Dawley (SD) rats with loperamide-induced constipation. The study included fecal analysis, gastrointestinal transit ratio, histopathological analysis, short chain fatty acids (SCFAs), and metagenome analysis. As results, the BIOVITA 3 group showed significant improvements in fecal number, water content, gastrointestinal transit ratio, and thickening of the mucosal layer. In the SCFAs analysis, all probiotic-treated groups showed an increase in total SCFAs compared to the loperamide-constipated group. Changes in microbial abundance and the diversity index of three groups (normal, constipated, and BIOVITA 3) were also defined. Of these, the BIOVITA 3 showed a significant improvement in loperamide-constipated SD-rats. This study suggests the possibility that BIOVITA 3 can be applied as an ingredient in functional foods to relieve constipation.

Keywords: constipation; probiotics; BIOVITA 3 bacterial species; gut microbiota
Introduction

Constipation is one of the most common gastrointestinal disorders and is associated with bowel obstruction, insufficient bowel movements, and the feeling of incomplete evacuation (Filipović et al., 2017). It is influenced by changes in diet and psychological and social factors, often leading to chronic gastrointestinal issues (Crowell et al., 2007). There is increasing interest in improving gastrointestinal disorders and alleviating fecal problems with probiotics (Zhao et al., 2015, Yu et al., 2017, Jung et al., 2022), such as *Bacillus* and *Lactobacillus*, as they have shown beneficial effects in improving intestinal health, including constipation, bowel movements, and intestinal barrier function (Rhayat et al. 2019, Zhang et al. 2023).

Probiotics are live microorganisms that confer health benefits on the host when administered in adequate amounts (Hill et al., 2014). Probiotics have been shown to have potential utility as a treatment for constipation with fewer side effects than chemical drugs. The existing research results indicate that probiotics can affect intestinal motility by altering the levels of neurotransmitters and short-chain fatty acids (SCFAs), and by regulating the gut microbiota and immunity (Dimidi et al., 2017). Numerous trials of probiotic supplementation have been conducted in animals and humans to test the efficacy of probiotics against constipation (Chen et al., 2020, Qiu et al., 2022).

BIOVITA 3 bacterial species (BIOVITA 3) is a freeze-dried probiotic blend powder that contains three spore-forming bacteria (*Clostridium butyricum* IDCC 1301, *Weizmannia coagulans* IDCC 1201, and *Bacillus subtilis* IDCC 1101). It was developed in 1959 and was the probiotic nutritional supplement in South Korea used to improve the function of children's intestines. BIOVITA 3 have different oxygen requirements, and consequently are known to proliferate throughout the gastrointestinal tract, from the small intestine to the large intestine, and exert positive effects on intestinal function (Kim, 2021).
A recent in vivo study found that *C. butyricum* IDCC 1301 improved high fat diet-induced colonic inflammation (Choi et al., 2023). *B. subtilis* IDCC 1101 and *W. coagulans* IDCC 1201 have been evaluated as safe probiotics for human use (Bang et al., 2021, Kim et al., 2022). Although the gut health benefits of their microbial components are expected, no studies have reported on the constipation improvement of blend probiotics BIOVITA 3. The purpose of this study therefore was to investigate the effects of BIOVITA 3 bacterial species on loperamide-induced constipation. Body weight, fecal parameters (fecal number and water content), gastrointestinal transit (GIT) ratio, and histopathological analyses were conducted, and changes in fecal short-chain fatty acids (SCFAs) and microbial communities were observed.

### Materials and Methods

#### Preparation of probiotics

*B. subtilis* IDCC 1101, *W. coagulans* (formerly *B. coagulans*, commercially *L. sporogenes*) IDCC 1201, and *C. butyricum* IDCC 1301 were obtained from Ildong Bioscience Co., Ltd (Pyeongtaek, South Korea). BIOVITA 3 was manufactured by mixing the three probiotics powder listed above (*B. subtilis* IDCC 1101, *W. coagulans* IDCC 1201, and *C. butyricum* IDCC 1301) while according to the in-house manual of Ildong Bioscience Co., Ltd (Pyeongtaek, South Korea) (Lot. No. ID-R0301).

#### Animals and reagents

Male Sprague-Dawley (SD) rats (6 weeks old) were purchased from Orientbio Inc., (Seongnam, South Korea), and housed two per cage. Animals were kept at a temperature of 22 ± 3°C and relative humidity of 30–70% and were given free access to tap water and a regular rodent diet (Envigo, Indianapolis, IN). Rats were acclimated for seven days prior to use and in vivo experiments were conducted in accordance with the
Efficacy Evaluation Center at Dt&CRO Co., Ltd. (220112, 2022.04.28). Loperamide hydrochloride (L0154) was purchased from Tokyo Chemical Industry Co., Ltd. (Tokyo, Japan). Phosphate-buffered saline (PBS, 10010023) was purchased from Gibco (Grand Island, NY). Dried starch was provided by Ildong Bioscience Co., Ltd. (Pyeongtaek, South Korea).

**Experimental design**

Rats were randomly divided into six groups (n = 10 per group): G1 (non-constipated group; Normal), G2 (loperamide-induced constipation group; Constipation), G3 (Bacillus subtilis IDCC 1101), G4 (Weizmannia coagulans IDCC 1201), G5 (Clostridium butyricum IDCC 1301), and G6 (BIOVITA 3). During the administration period, constipation was induced by the oral administration of loperamide (4 mg/kg) for seven days in rats in all groups except for G1. Starch (probiotic powder excipient) or probiotic powder was orally administered to the rats in each group for seven days. Rats in the G1 and G2 groups were orally administered 0.2 g of starch. Rats in the test groups were orally administered probiotic powder at $1.0 \times 10^9$ CFU/day. All administered samples were dissolved in PBS before use. Body weights and food and water intake were recorded daily. All rats were euthanized at the end of the administration period, and fecal and colon tissue samples were collected for subsequent analysis.

**Fecal number and water content**

Fecal pellets in cages were collected on the sixth day of administration. The collected feces were counted and measured as the fecal pellet weight. After drying in the oven at 60°C for 24 h, the feces were weighed. The water content (%) in fecal samples was calculated as follows: $(\text{initial weight of feces} - \text{dried weight of feces})/\text{initial weight of feces} \times 100$. All feces were stored at -80°C for subsequent analysis.
Intestinal transit ratio

The intestinal transit ratio was measured by a modification of the method of Xu et al. (2012). Rats were fasted for 18 h on the last day of treatment and administered loperamide and the test substances. Then, a charcoal meal (10% charcoal powder) and 5% arabic gum were immediately administered. All rats were fasted and denied water for 30 min, euthanized by CO₂ inhalation, and their intestines were excised. Total intestinal length and distance traveled by the charcoal meal were measured. The intestinal transit ratio (%) was calculated as the transit distance of the charcoal meal/total length of the intestinal tract x 100.

Histological analysis by hematoxylin and eosin staining

Colon tissues were fixed in 10% formaldehyde, dehydrated, and embedded in paraffin. Then, 5 μm sections were prepared and stained with hematoxylin and eosin (H&E). Pathological changes were observed using an E600 (Nikon, Japan) research microscope.

SCFAs analysis

SCFAs were quantitated with a high-performance liquid chromatography-ultraviolet (HPLC-UV) system according to the method of Leite et al. (2023). Feces (1 g) were extracted with 8 mL of distilled water by vortexing for 15 min. The extracted samples were centrifuged for 15 min, 9,000 rpm at 4°C. The supernatant was filtered through a 0.45 μm Millipore filter (Whatman, Kent, UK), and the filtrate was injected by HPLC (Alliance e2695; Waters Corp.) equipped with a UV detector (2998; Waters Corp.) and a COREGEL 87H3 C₁₈ column (7.8 mm x 300 mm x 5 μm; Concise Separations, USA). The column temperature was set at 35°C, and the sample tray temperature was set at 4°C. The mobile phase was 5 nM H₂SO₄ in water and the flow rate was 0.6 mL/min. The injection volume was 10 μL and the detection wavelength was 210 nm.
concentrations of acetic, propionic, and butyric acid were determined by constructing
calibration curves using the respective standard reagents.

16S rRNA-based metagenomic analysis

16S rRNA gene sequencing was performed to analyze the microbiome in SD rats
with loperamide-induced constipation. DNA was extracted using a PowerSoil® DNA
Isolation Kit (Cat. No. 12888, MO BIO, Carlsbad, CA, USA) according to the
manufacturer’s instructions. Each sample was prepared according to Illumina
Sequencing Library protocols. Extracted DNA was amplified with V3–V4 region and
sequenced using MiSeq™ (Illumina, San Diego, CA, USA) by Macrogen (Seoul, South
Korea). The microbiome was investigated using the 16S rRNA gene-based Microbial
Taxonomic Profiling (MTP) platform of EzBioCloud Apps (ChunLab, Seoul, South
Korea). ChunLab’s 16S rRNA database (DB ver. PKSSU4.0) was used for the
taxonomic assignment of 16S rRNA amplicon reads (Yoon et al., 2017). Alpha diversity
and beta diversity were subsequently analyzed. Alpha diversity was evaluated by ACE,
Chao1, Shannon, and Simpson indices. Beta diversity was investigated by generalized
UriFrac, using principal coordinates analysis (PCoA) to analyze the differences between
samples. Linear discriminant analysis (LDA) effect size was analyzed using the linear
discriminant analysis effect size (LEfSe) algorithm to identify the bacterial biomarkers
differentially represented between the groups at different taxonomic levels.
Statistical analysis

The results were analyzed using the Statistical Package for Social Sciences version 27.0 (SPSS, Chicago, IL) and are presented as the mean ± standard deviation (SD). An analysis of variance (ANOVA) test was used to determine differences among samples at a significance level of \( p < 0.05 \). Microbial taxonomic abundance and gut microbiota diversity were compared using the Wilcoxon rank-sum test in the EzBioCloud Apps platform (ChunLab, Seoul, South Korea).
**Results and Discussion**

**Part I: Effect of BIOVITA 3 and its component strains in SD-rats with loperamide-induced constipation**

**Body weight and food efficiency ratio (FER)**

No significant differences in body weights ($p > 0.05$) were seen among the groups (Fig. 1a). Body weights increased from 247.6 – 250.8 g on day 1 to 282.2 – 289.3 g on day 6 of the administration period. The body weight gain, food intake, and FER of group G1-G6 are shown in Table.1. There was no significant difference ($p > 0.05$) in body weight gain among all groups (G1-G6). There was no significant difference ($p > 0.05$) in food intake among all groups except G6. Following the induction of constipation, the food intake of the G6 group (21.3 g/day) was significantly lower ($p < 0.05$) than that of the G1 group (24.6 g/day). However, the FER of the G6 was not significantly different from those of the other groups (G1-G5). The FER for all groups (G1-G6) ranged from 0.29 to 0.33, with no significant difference in FER among groups.

**Fecal number and water content**

The fecal number and water content of feces were measured to investigate the fecal parameters of rats with loperamide-induced constipation treated with the three IDCC strains and BIOVITA 3. The average numbers of fecal pellets per cage were 32.3, 2.6, 4.0, 3.0, 8.8, and 8.2 in G1-G6 groups, respectively (Fig. 1b). A statistically significant decrease ($p < 0.01$) in fecal number was seen in the G2 with constipation compared to G1. Statistically significant increases ($p < 0.01$) in the fecal number were seen in the G5 and G6 groups compared to G2. The water content in each group (G1-G6) was 39.8, 29.7, 36.6, 41.5, 42.7, and 48.2%, respectively (Fig. 1c). A significant reduction was seen in the G2 group ($p < 0.01$) compared to the G1 group. However, there were statistically
significant increases in the G3 ($p < 0.05$), G5 ($p < 0.05$), and G6 ($p < 0.01$) groups compared to G2. Therefore, the results of the G2 group confirmed that loperamide-induced constipation in SD rats, and that the IDCC strains and BIOVITA 3 had significant effects on fecal number and water content in constipated groups.

**Gastrointestinal transit ratio**

Intestinal transit times reflect intestinal motility, which can be assessed by the transit speed of the digestive tract (Kim et al., 2017, Inatomi and Honma, 2021). The intestinal charcoal transit ratio is important in the diagnosis of constipation and for the G1-G6 groups were 72.1, 70.4, 78.6, 77.2, 75.4, and 77.3%, respectively, as shown in Fig. 1d. The transit ratio in G2 decreased by 1.7% compared to G1, but the differences between the two groups were not significant ($p > 0.05$). There was a statistically significant increase in probiotic-treated groups G3 ($p < 0.05$), G5 ($p < 0.01$), and G6 ($p < 0.01$) compared to G2.

**Histological analysis of colon tissue**

To confirm that probiotics could alleviate the histopathological alterations in constipated SD rats, H&E staining was performed to observe the morphology of the colon. As shown in Fig. 2b, the mucosal layer length of G2 (272.0 μm) was significantly lower than that of G1 (322.4 μm), and all groups treated with probiotic powders showed increased lengths, compared to G2. In particular, there was a significant difference in the G6 ($p < 0.05$) compared to the G2. In terms of the muscle layer, the G2 (156.4 μm) was significantly shorter than that of the G1 (207.2 μm) (Fig. 2c). G3 (183.2 μm), G4 (207.4 μm), G5 (184.6 μm), and G6 (162.6 μm) showed increased lengths compared to G2. Among them, G4 was significantly different ($p < 0.01$) compared to G2. The results of this study were consistent with previous studies in which the thickness of the mucosal...
layer of colonic tissue decreased in the constipation-induced group compared to the normal group, while it increased in the probiotic-treated group (Kim et al., 2015, Kim et al., 2017). The mucosal layer and muscle layer of colon tissue play important roles in both maintaining intestinal functions (intestinal motility, absorption and secretion, immune function, etc.) and creating a healthy gut environment. These results showed that G4 and G6 significantly improved the muscle layer and mucosal layer, respectively. Moreover, when leukocyte infiltration was observed in colon tissue, the number of animals observed was reduced in both G4 (n=2) and G6 (n=1) compared to G2 (n=4), while the frequency of inflammation was reduced in BIOVITA 3 (G6), thus indicating an improvement over G4. Consequently, most of the constipation improvement scores showed significant improvements with the G6.

Several studies have reported improvements in constipation by the oral administration of probiotics to loperamide-induced SD rats. In this model, the fecal number, water content, and gastrointestinal transit ratio decreased in the constipation-induced group compared to the normal group, while these constipation indicators increased in the probiotic-treated group, thus alleviating constipation symptoms (Kim et al., 2015, Inatomi and Honma, 2021, Jung et al., 2022). Furthermore, several studies have compared and analyzed the improvement in constipation by treatment with single and mixed probiotic strains, and these also demonstrated that mixed strains were more effective in improving constipation (Kim et al., 2017, Cheng et al., 2023). These previous research findings are consistent with our results, in which we found that BIOVITA 3 (mixed strains) had a therapeutic effect in alleviating constipation.
Part II: Effect of BIOVITA 3 on SCFAs production and Gut Microbiome

Fecal SCFAs production

SCFAs are primary metabolites that are produced by gut microbiota or probiotics, which are mainly composed of acetic acid, propionic acid, and butyric acid. (Shi et al., 2016). The concentration of SCFAs in the fecal samples were analyzed by HPLC-UV. Acetic, propionic, butyric acid, and total SCFAs content in the G2 were reduced compared to the G1, confirming the induction of constipation (Table. 2). The total SCFAs content in G2 (1638.18 ppm) was significantly lower than that in G1 (2690.05 ppm). The three IDCC groups (G3 – G5) and the BIOVITA 3 group (G6) all showed increased acetic acid, propionic acid, and total SCFAs compared to the G2 group. The total SCFAs content of G4 (3673.67 ppm) and G6 (3893.55 ppm) was significantly increased compared to G2 (p < 0.05) and was highest in G6. G5 showed an increase in butyric acid compared to G2, which is considered to be the effect of C. butyricum IDCC 1301, which has the ability to produce butyric acid. These results are consistent with previous studies that reported increased SCFAs when probiotics were administered in loperamide-induced constipation (Kim et al., 2015, Kim et al., 2017, Cheng et al., 2023).

The three SCFAs play an important role in human health with physiological activities ranging from immune system regulation to metabolic pathway modulation (Xiong et al., 2022). Increased SCFAs in the colon have been correlated with a reduced risk of certain conditions including constipation and cancer (Hooper et al. 2002), and the content of fecal SCFAs was reported to be significantly lower in constipated patients than in healthy individuals (Shi et al., 2016). SCFAs are anions in the colon that promote the absorption of sodium and water, promote the proliferation of colonic epithelial cells and mucosal growth, and act as important nutrients (Ruppin et al., 1980, Fukunaga et al., 2003). Acetic
acid and butyric acid released in the colon have been shown to increase water content and
gastrointestinal transit rate, and to alleviate the symptoms of constipation in a microbial-
dependent manner (Wang et al., 2020). Therefore, an increase in total SCFAs is associated
with constipation relief. We consider it to be the case that BIOVITA 3 and its component
strain administered in this study increased total SCFAs in loperamide-induced constipated
rats, thereby improving fecal water content and GIT, and ultimately relieving constipation.

However, the profile of fecal SCFAs in this study exhibited some differences from
previous studies, with the content of propionate being higher than acetate. Acetate was
predominant on the second day of administration (data not shown), but propionate was
predominant on the sixth day. According to Annison et al. (2003) "SCFAs can be sensitive
to changes in substrate supply," and the ratio of acetate, propionate, and butyrate was
shown to vary depending on the type of starch. We conclude that the proportion of SCFAs
changed because of the effect of the test substances during the administration period.

**Alteration of taxonomic composition**

At the phylum level, *Firmicutes* and *Bacteroides* were the major gut microbiota in SD
rats (Fig. 3a). At the family level, *Porphyromonadaceae* was only found in rats in the G6
group (Fig. 3b). We primarily found increases in the genus *Parabacteroides*. These
bacteria were recently reported to enhance the physiological properties of carbohydrate
metabolism and the secretion of SCFAs (Wang et al., 2019, Cui et al., 2022).

*Enterobacteriaceae* appear similar in G1 and G6 but not in G2.

**Change of microbial diversity**

The alpha diversity index was analyzed by species richness (ACE and Chao 1) and
community diversity indices (Shannon and Simpson). There was a significant difference
in the ACE and Chao1 indices between the G1 group and loperamide-induced constipated
groups (G2 and G6), but there were no significant differences between the G2 and G6
groups (Fig. 3c). The Shannon index, which is an indicator of microbiota diversity, was
significantly different between the loperamide-induced constipated groups (G2 and G6)
and the G1 group. An increased Shannon index was seen in G6 compared to G2, but the
difference was not significant (Fig. 3d). The Simpson index showed a contrasting trend
with the Shannon index, indicating increased microbial diversity. The PCoA of beta
diversity at the genus level showed that the three groups (n=6) were divided into PC1
(32.61%) and PC2 (21.88%) (Fig. 3e). There was a significant difference between G2 and
G6 (p < 0.01).

Core gut microbiota analysis using linear discriminant analysis effect size

This study utilized the LEfSe algorithm to identify core gut microbiota for constipation
responses to probiotic treatment. Fecal samples from the G1, G2, and G6 groups were
analyzed at the genus and species levels (Fig. 4). The results showed that the loperamide-
induced constipation samples (G2) had a higher abundance of *Lactobacillus* and a lower
abundance of *Romboutsia, Turicibacter,* and *Pseudoflavonifractor* than the normal
samples in the G1 group. Additionally, *Ruminococcus* and *Fusicatenibacter* were
identified as core gut microbiota for treatment responses in the G6 group, whereas
*Lactobacillus* was identified as core gut microbiota in the G2 group. Furthermore,
EU622720_s, *Lactobacillus reuteri* group, *Blautia faecis,* and *Fusicatenibacter
saccharivorans* were identified as core gut microbiota in the G6 group, whereas
FJ880321_s and *Lactobacillus intestinalis* were identified as core gut microbiota in the
G2 group.

*Ruminococcus* and *Fusicatenibacter* are fiber-degrading bacteria that produce SCFAs
as a byproduct of fiber fermentation (Belenguer et al., 2007). The bacterial-derived SCFAs
are known to play a role in promoting healthy bowel movements by stimulating the
growth of beneficial bacteria, reducing inflammation, and improving gut motility (Den
Besten et al., 2013). *Limosilactobacillus reuteri* is a bacterium that produces luterin, an
antibacterial substance that has antibacterial activity against pathogenic microorganisms
(Kim et al., 2015). Recently, *Blautia facis* has been found to be a acetic acid-producing
bacterium belonging to the genus *Blautia* that has attracted substantial attention as a gut
microbiota that brings about potential health benefits such as the prevention of respiratory
infections and anti-inflammatory effects (Liu et al., 2021, Verstraeten et al., 2022).
Therefore, the increase in these beneficial microbes (*Ruminococcus, Fusicatenibacter, L.
reuteri, B. facis*) in the BIOVITA 3 group might have indirectly contributed to an
improved gut environment, in addition to increased gut motility due to SCFA production.
This also indicates that an increase in these genera may be a response to increased dietary
fiber intake, which in turn, promotes healthy bowel movements. Further research will be
needed to confirm these hypotheses.
Conclusion

The effect of BIOVITA 3 on loperamide-induced constipation was investigated in SD rats by analyzing the fecal characteristics (fecal number, water content), intestinal transit time, colonic morphology, SCFAs production, and gut microbiota.

The primary results of this study were as follows: First, this study confirmed the loperamide-induced constipation model. Second, single or blend probiotics were administered orally, and the blend probiotic BIOVITA 3 effectively improved constipation symptoms, significantly increasing fecal numbers, the fecal water content, GIT ratio, and the mucosal layer in colon. Third, BIOVITA 3 had a beneficial effect on alleviating constipation by altering the gut microbiome and increasing total SCFAs, which play an important role in promoting bowel regularity, maintaining intestinal barrier integrity, and regulating immune function.

In this study, BIOVITA 3 showed better effects in relieving constipation than using probiotics alone. We believe that the synergistic effects of the three probiotic-specific strains in BIOVITA 3 led to effects on improving constipation, and one of the key mechanisms is thought to be the production of SCFAs in the gut. The BIOVITA 3 increased the production of SCFAs in the gut, which led to improved GIT by promoting intestinal motility, increased fecal water content through enhanced water absorption, increased bowel movement frequency, and, ultimately, relief of constipation symptoms. We also suggest that BIOVITA 3 increases useful microorganisms and changes intestinal microbial diversity, and that it has the potential to maintain, and improve host intestinal health. The results strongly suggest that BIOVITA 3 supplementation has the potential to be developed as a therapeutic and preventive strategy for constipation. Further research is needed to understand the mechanisms of action by which these probiotics improve constipation.
Conflicts of Interest

No potential conflict of interest relevant to this article was reported.

Acknowledgments

This research was supported by "Regional Innovation Strategy (RIS)" through the National Research Foundation of Korea(NRF) funded by the Ministry of Education(MOE)(2021RIS-001). We would deeply be thankful to Ildong Bioscience Co., Ltd. for providing the BIOVITA 3 and its three strains used as experimental materials for this study.

Author Contributions

Conceptualization: Oh I
Data curation: Jang YJ
Formal analysis: Moon JS, Kim D
Methodology: Kim JE
Validation: Choi HS
Investigation: Kim JE
Writing - original draft: Jang YJ
Writing - review & editing: All authors

Funding

This research received no external funding.

Ethics Approval

This animal study was conducted with the approval of the Experimental Animal Ethics Committee at Dt&CRO (Yongin, South Korea) (approval number: 220112, study number: DTE220027).
References


Chen C, Chao S, Pan T. 2020. Lactobacillus paracasei subsp. paracasei NTU 101 lyophilized powder improves loperamide-induced constipation in rats. Heliyon. 6


**Figure legend**

Fig. 1 Effect of BIOVITA 3 and its component strains treatment of loperamide-induced constipated SD rats. (a) Change in body weight, (b) Number of feces per cage, (c) Water content (%) in fecal, and (d) Gastrointestinal charcoal transit ratio (%). Bars represent the mean ± SD (n = 10). ††p <0.01 vs. G1, *p <0.05 and **p <0.01 vs. G2. G1, normal group; G2, loperamide-induced constipation group; G3: *B. subtilis* IDCC 1101 and loperamide-induced constipation group; G4: *W. coagulans* IDCC 1201 and loperamide-induced constipation group; G5: *C. butyricum* IDCC 1301 and loperamide-induced constipation group; G6: BIOVITA 3 and loperamide-induced constipation group.

Fig. 2 Histological analysis of colon tissue stained with H&E. (a) Photographs of colon sections, (b) Mucosal layer length. (c) Muscle layer length. †p <0.05 vs. G1, *p <0.05 and **p <0.01 vs. G2. G1, normal group; G2, loperamide-induced constipation group; G3: *B. subtilis* IDCC 1101 and loperamide-induced constipation group; G4: *W. coagulans* IDCC 1201 and loperamide-induced constipation group; G5: *C. butyricum* IDCC 1301 and loperamide-induced constipation group; G6: BIOVITA 3 and loperamide-induced constipation group.

Fig. 3 Comparative analysis of the fecal microbiome in loperamide-induced constipated SD rats. (a) Taxonomic abundance at the phylum level and (b) family level. (c) Alpha-diversity index values were statistically analyzed by the Wilcoxon rank-sum test. (d) Principal coordinate analysis (PCoA) of beta-diversity. *p < 0.05 and **p < 0.01, significantly different by PERMANOVA. G1: normal group; G2: loperamide-induced constipation group; G6: BIOVITA 3 and loperamide-induced constipation group.
Fig. 4 Core gut microbial analysis in SD rats with loperamide-induced constipation by treated probiotics. The biomarkers identified by the linear discriminant analysis (LDA) effect size algorithm are shown with heat maps of the log-scaled relative abundance. Each plot represents biomarkers in the fecal samples in the G1, G2, and G6 groups at the genus level (A) and species level (B) (n = 8 in each group).
Table 1: Body weight gain, food intake, and food efficiency ratio in SD rats with loperamide-induced constipation.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>G1</th>
<th>G2</th>
<th>G3</th>
<th>G4</th>
<th>G5</th>
<th>G6</th>
</tr>
</thead>
<tbody>
<tr>
<td>Constipation²</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Body weight gain (g/day)</td>
<td>8.0±0.9</td>
<td>7.3±1.1</td>
<td>6.9±1.4</td>
<td>7.7±1.6</td>
<td>7.7±0.8</td>
<td>6.6±1.4†</td>
</tr>
<tr>
<td>Food intake (g/day)</td>
<td>24.6±0.9</td>
<td>22.9±1.1</td>
<td>23.8±1.1</td>
<td>24.3±1.2</td>
<td>22.8±1.3</td>
<td>21.3±1.4</td>
</tr>
<tr>
<td>FER*</td>
<td>0.33±0.04</td>
<td>0.32±0.07</td>
<td>0.29±0.07</td>
<td>0.32±0.08</td>
<td>0.34±0.05</td>
<td>0.31±0.09</td>
</tr>
</tbody>
</table>

¹ G1: Normal group; G2: loperamide-induced constipation group; G3: *B. subtilis* IDCC 1101 and loperamide-induced constipation group; G4: *W. coagulans* IDCC 1201 and loperamide-induced constipation group; G5: *C. butyricum* IDCC 1301 and loperamide-induced constipation group; G6: BIOVITA 3 and loperamide-induced constipation group.

² (-): Constipation not induced, (+): Constipation induced. * Food efficiency ratio (FER) = body weight gain (g)/ food intake (g). † p < 0.05 vs. G1 by ANOVA test.
Table. 2 The concentration of short-chain fatty acids (SCFAs) in SD rats with loperamide-induced constipation.

<table>
<thead>
<tr>
<th>Groups</th>
<th>The concentration of short-chain fatty acids (SCFAs, ppm)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Acetic acid</td>
</tr>
<tr>
<td>G1</td>
<td>965.90 ± 117.38</td>
</tr>
<tr>
<td>G2</td>
<td>673.93 ± 191.19 †</td>
</tr>
<tr>
<td></td>
<td>50.45 ±</td>
</tr>
<tr>
<td>G3</td>
<td>836.04 ± 345.12</td>
</tr>
<tr>
<td></td>
<td>1219.60 ±</td>
</tr>
<tr>
<td>G4</td>
<td>203.51†</td>
</tr>
<tr>
<td></td>
<td>62.03±124.0</td>
</tr>
<tr>
<td>G5</td>
<td>1207.09 ± 318.78</td>
</tr>
<tr>
<td></td>
<td>1292.25 ±</td>
</tr>
<tr>
<td>G6</td>
<td>209.91†</td>
</tr>
</tbody>
</table>

† G1: Normal group; G2: loperamide-induced constipation group; G3: B. subtilis IDCC 1101 and loperamide-induced constipation group; G4: W. coagulans IDCC 1201 and loperamide-induced constipation group; G5: C. butyricum IDCC 1301 and loperamide-induced constipation group; G6: BIOVITA 3 and loperamide-induced constipation group.

Values are means ± SD (n= 10). †p < 0.05 vs. G1, *p < 0.05 vs. G2.
Fig. 1 Effect of BIOVITA 3 and its component strains treatment of loperamide-induced constipated SD rats. (a) Change in body weight, (b) Number of feces per cage, (c) Water content (%) in fecal, and (d) Gastrointestinal charcoal transit ratio (%). Bars represent the mean ± SD (n = 10). ††p < 0.01 vs. G1, *p < 0.05 and **p < 0.01 vs. G2. G1, normal group; G2, loperamide-induced constipation group; G3: B. subtilis IDCC 1101 and loperamide-induced constipation group; G4: W. coagulans IDCC 1201 and loperamide-induced constipation group; G5: C. butyricum IDCC 1301 and loperamide-induced constipation group; G6: BIOVITA 3 and loperamide-induced constipation group.
Fig. 2 Histological analysis of colon tissue stained with H&E. (a) Photographs of colon sections, (b) Mucosal layer length. (c) Muscle layer length. †p < 0.05 vs. G1, *p < 0.05 and **p < 0.01 vs. G2. G1, normal group; G2, loperamide-induced constipation group; G3: *B. subtilis* IDCC 1101 and loperamide-induced constipation group; G4: *W. coagulans* IDCC 1201 and loperamide-induced constipation group; G5: *C. butyricum* IDCC 1301 and loperamide-induced constipation group; G6: BIOVITA 3 and loperamide-induced constipation group.
Fig. 3 Comparative analysis of the fecal microbiome in loperamide-induced constipated SD rats.
(a) Taxonomic abundance at the phylum level and (b) family level. (c) Alpha-diversity index values were statistically analyzed by the Wilcoxon rank-sum test. (d) Principal coordinate analysis (PCoA) of beta-diversity. *p < 0.05 and **p < 0.01, significantly different by PERMANOVA. G1: normal group; G2: loperamide-induced constipation group; G6: BIOVITA 3 and loperamide-induced constipation group.
Fig. 4 Core gut microbial analysis in SD rats with loperamide-induced constipation by treated probiotics. The core microbiota identified by the linear discriminant analysis (LDA) effect size algorithm is shown with heat maps of the log-scaled relative abundance. Each plot represents biomarkers in the fecal samples in the G1, G2, and G6 groups at the genus level (a) and species level (b) (n = 8).